教授　鈴木忠樹
ページタイトル画像

鈴木忠樹（https://researchmap.jp/tadakisuzuki）

2002年、北大医学部を卒業後、ただちに同大学院医学研究科博士課程に進学。大学院では分子細胞病理学分野にて外科病理学の研鑽とともに神経ウイルス感染症研究について学位取得。2006年に大学院修了後、北海道大学人獣共通感染症リサーチセンター分子病態診断部門にて学振特別研究員（PD）および博士研究員としてウイルス学研究に従事。2009年、国立感染症研究所（感染研）感染病理部に着任。感染研では、病理学とウイルス学を背景として新興感染症の感染病理学研究に従事するとともにワクチン学研究の基本を学ぶ。2013年、感染病理部第四室 室長に昇任。2015年から１年間、米国CDCにて感染病理学診断の研鑽を積むとともに先天性ジカ症候群の感染症対策に従事。2020年より感染病理部長として、新型コロナパンデミック初期より感染病理学の立場から感染症研究と感染症対策に従事。2025年4月より、感染研と国立国際医療研究センターが統合し発足した国立健康危機管理研究機構とのクロスアポイントメントのもと感染病理部長として感染病理部を統括しつつ、千葉大学大学院医学研究院 感染病態学 教授に着任。現在の研究テーマは、新興感染症の病因病態解明と感染症予防ワクチンの有効性発現機構解明、新規ワクチンの開発。

 

【免許・資格等】

医師免許（2002年）

死体解剖医資格（2007年）

日本病理学会認定専門医（2012年）

北海道大学Zoonosis Control Expert（2013年）

病理専門医研修指導医（2018年）

実験室バイオセーフティ専門家（2024年）

 

【受賞歴等】

日本ウイルス学会杉浦奨励賞（2013年）

日本ワクチン学会高橋奨励賞（2016年）

The Nakano Citation Award of NCEZID,CDC, USA(2017年)

多ヶ谷勇記念ワクチン研究イスクラ奨励賞（2020年）

Clarivate Highly Cited Researcher 2023(Cross-Field)（2023年）

Clarivate Highly Cited Researcher 2024(Cross-Field)（2024年）

 

【所属学会】

日本ワクチン学会

日本神経感染症学会

日本病理学会

日本ウイルス学

日本臨床ウイルス学会

日本分子生物学会

 

【委員会活動等】

WHO Technical Advisory Group on Virus Evolution専門家

【主要な研究業績】

  1. Osawa S, Miyazaki K, Mine S, Hirata Y, Terada N, Ozawa M, Kikuchi K, Uchida A, Hirose K, Imakawa Y, Komuro K, Nagata N, Abe S, Uchida Y, Yanaoka T, Ozono S, Yoshikawa T, Lim CK, Fukushi S, Matsuu A, Miyamoto S, Kataoka M, Katano H, Maeda K, Ebihara H, Suzuki T*. Fulminant Viral Myocarditis Associated with Thogotovirus. N Engl J Med. 2025 Sep 4;393(9):924-926. doi: 10.1056/NEJMc2503343. *Corresponding author
  2. Vakaniaki EH*, Kuispond NS*, Hirata Y*, Bangwen E, Brosius I, Kinganda-Lusamaki E, Ozono S, Katano H, Ndunge LG, Mulopo-Mukanya N, Tshomba JC, De Vos E, Van Dijck C, Munganga P, Mukari G, Mujula Y, Mambo DM, Kitwanda SB, Maliyamungu-Bubala N, Mutimbwa-Mambo L, Crozier I, Dodd LE, Tshiani-Mbaya O, Lebwaze BM, Malembaka EB, Barhishindi I, Krasemann S, Colebunders R, Katoto PDMC, Makiala-Mandanda S, Kindrachuk J, Rimoin AW, Muyembe-Tamfum JJ, Mukadi-Bamuleka D, Wawina-Bokalanga T, Nundu SS, Suzuki T*, Chirimwami RB*, Liesenborghs L*, Mbala-Kingebeni P*. Three Cases of Vertical Transmission of Clade Ib Mpox Virus. N Engl J Med. 2025 Jun 19;392(23):2385-2387. doi: 10.1056/NEJMc2503347. *Contributed equally
  3. Miyamoto S, Numakura K, Kinoshita R, Arashiro T, Takahashi H, Hibino H, Hayakawa M, Kanno T, Sataka A, Sakamoto R, Ainai A, Arai S, Suzuki M, Yoneoka D, Wakita T, Suzuki T*. Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history. Commun Med (Lond). 2025 May 15;5(1):172. doi: 10.1038/s43856-025-00894-8. *Corresponding author
  4. Takahashi K, Sato Y, Hasegawa H, Katano H*, Suzuki T*. Histomorphological variations in progressive multifocal leukoencephalopathy correlated with JCV replication in brain lesions: insights from 91 patients. Acta Neuropathol Commun. 2025 May 19;13(1):106. doi: 10.1186/s40478-025-02027-7. *Corresponding authors
  5. Kinoshita R, Miyamoto S, Sakuraba S, Sugihara J, Suzuki M, Suzuki T*, Yoneoka D*. Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023. Emerg Infect Dis. 2024 Jun;30(6):1267-1270. doi: 10.3201/eid3006.231454. *Corresponding authors
  6. Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, Ozono S, Aihara K, Takahashi K, Tsuchihashi Y, Ishikane M, Arashiro T, Saito S, Ainai A, Hirata Y, Iida S, Katano H, Tobiume M, Tokunaga K, Fujimoto T, Suzuki M, Nagashima M, Nakagawa H, Narita M, Kato Y, Igari H, Fujita K, Kato T, Hiyama K, Shindou K, Adachi T, Fukushima K, Nakamura-Uchiyama F, Hase R, Yoshimura Y, Yamato M, Nozaki Y, Ohmagari N, Suzuki M, Saito T, Iwami S*, Suzuki T*. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2314808120. doi: 10.1073/pnas.2314808120. *Corresponding authors
  7. Miyamoto S, Kuroda Y, Kanno T, Ueno A, Shiwa-Sudo N, Iwata-Yoshikawa N, Sakai Y, Nagata N, Arashiro T, Ainai A, Moriyama S, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Fukushi S, Takahashi Y, Maeda K, Suzuki T*. Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval. iScience. 2023 May 19;26(5):106694. doi: 10.1016/j.isci.2023.106694. *Corresponding author
  8. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B*, Imai M*, Suzuki T*, Kawaoka Y*. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun. 2023 Mar 23;14(1):1620. doi: 10.1038/s41467-023-37059-x. *Corresponding authors
  9. Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T*. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. iScience. 2023 Feb 17;26(2):105969. doi: 10.1016/j.isci.2023.105969. PMID: 36687316; PMCID: PMC9837220. *Corresponding author
  10. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M*, Suzuki T*, Kawaoka Y*. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature. 2022 Dec;612(7940):540-545. doi: 10.1038/s41586-022-05482-7. PMID: 36323336. *Corresponding authors
  11. Takahashi K, Ishikane M*, Ujiie M, Iwamoto N, Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, Kanno T, Saito S, Miyamoto S, Ainai A, Tobiume M, Arashiro T, Fujimoto T, Saito T, Yamato M, Suzuki T*, Ohmagari N. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees. Emerg Infect Dis. 2022 Mar 15;28(5). doi: 10.3201/eid2805.220197. *Corresponding authors
  12. Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Ken M, Fukushi S*, Takahashi Y*, Suzuki T*. Vaccination- infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med. 2022 Mar 4;3(4):249–261.e4. doi: 10.1016/j.medj.2022.02.006. *Corresponding authors
  13. Wada Y, Miyamoto S, Iida S, Sano K, Sato Y, Ainai A, Saito K, Katano H, Hasegawa H, Suzuki T*. Propagation of activated B cells by in vitro SFTSV infection of human peripheral blood mononuclear cells. J Infect Dis. 2021 Jul 5:jiab343. doi: 10.1093/infdis/jiab343. *Corresponding author
  14. Tsukamoto T, Nakajima N, Sakurai A, Nakajima M, Sakurai E, Sato Y, Takahashi K, Kanno T, Kataoka M, Katano H, Iwata M, Doi Y, Suzuki T*. Lung Pathology of Mutually Exclusive Co-infection with SARS-CoV-2 and Streptococcus pneumoniae. Emerg Infect Dis. 2021 Jan 14;27(3). doi: 10.3201/eid2703.204024. *Corresponding author
  15. Sano K, Saito S, Suzuki T*, Kotani O, Ainai A, van Riet E, Tabata K, Saito K, Takahashi Y, Yokoyama M, Sato H, Maruno T, Usami K, Uchiyama S, Ogawa-Goto K, Hasegawa H*. An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody. PLoS One. 2021 Jan 7;16(1):e0245244. doi: 10.1371/journal.pone.0245244. eCollection 2021. *Corresponding author
  16. Adachi T, Chong JM, Nakajima N, Sano M, Yamazaki J, Miyamoto I, Nishioka H, Akita H, Sato Y, Kataoka M, Katano H, Tobiume M, Sekizuka T, Itokawa K, Kuroda M, Suzuki T*. Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, Japan. Emerg Infect Dis. 2020 May 15;26(9). doi: 10.3201/eid2609.201353. *Corresponding author
  17. Suzuki T*, Sato Y, Sano K, Arashiro T, Katano H, Nakajima N, Shimojima M, Kataoka M, Takahashi K, Wada Y, Morikawa S, Fukushi S, Yoshikawa T, Saijo M, Hasegawa H*. Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections. J Clin Invest. 2020 Feb 3;130(2):799-812. doi: 10.1172/JCI129171. *Corresponding authors
  18. Saito S, Sano K, Suzuki T*, Ainai A, Taga Y, Ueno T, Tabata K, Saito K, Wada Y, Ohara Y, Takeyama H, Odagiri T, Kageyama T, Ogawa-Goto K, Multihartina P, Setiawaty V, Pangesti KNA, Hasegawa H*. IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody. PLoS Pathog. 2019 Jan 3;15(1):e1007427. *Corresponding authors
  19. Tazaki T, Tabata K, Ainai A, Ohara Y, Kobayashi S, Ninomiya T, Orba Y, Mitomo H, Nakano T, Hasegawa H, Ijiro K, Sawa H, Suzuki T*, Niikura K*. Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines. RSC Adv. 2018;8:16527-16536. *Corresponding authors
  20. Kawaguchi A, Suzuki T*, Ohara Y, Takahashi K, Sato Y, Ainai A, Nagata N, Tashiro M, Hasegawa H. Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection. PLoS One. 2017 Feb 28;12(2):e0173008. *Corresponding author
  21. Suzuki T, Kawaguchi A, Ainai A, Tamura S, Ito R, Multihartina P, Setiawaty V, Pangesti KN, Odagiri T, Tashiro M, Hasegawa H. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7809-14.
  22. Takahashi T*, Maeda K*, Suzuki T*, Ishido A, Shigeoka T, Tominaga T, Kamei T, Honda M, Ninomiya D, Sakai T, Senba T, Kaneyuki S, Sakaguchi S, Satoh A, Hosokawa T, Kawabe Y, Kurihara S, Izumikawa K, Kohno S, Azuma T, Suemori K, Yasukawa M, Mizutani T, Omatsu T, Katayama Y, Miyahara M, Ijuin M, Doi K, Okuda M, Umeki K, Saito T, Fukushima K, Nakajima K, Yoshikawa T, Tani H, Fukushi S, Fukuma A, Ogata M, Shimojima M, Nakajima N, Nagata N, Katano H, Fukumoto H, Sato Y, Hasegawa H, Yamagishi T, Oishi K, Kurane I, Morikawa S, Saijo M. The First Identification and Retrospective Study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 2014 Mar;209(6):816-27. *co-first authors
  23. Suzuki T, Orba Y, Makino Y, Okada Y, Sunden Y, Hasegawa H, Hall WW, Sawa H. Viroporin activity of the JC polyomavirus is regulated by interactions with the adaptor protein complex 3. Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18668-73.
  24. Suzuki T, Yamanouchi S, Sunden Y, Orba Y, Kimura T, Sawa H. Natalizumab Has No Direct Biological Effect on JC virus Infectivity in Permissive Human Neural Cell Lines. J Med Virol, 2010 Jul;82(7):1229-35.
  25. Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, Tanaka S, Nagashima K, Hall WW, Sawa H. The human polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog, 2010;6(3):e1000801.